首页> JHEP reports : innovation in hepatology> Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial).

Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial).

导出 LinkOut

翻译打印收藏纠错

第一作者： Fabienne,Marcellin

第一单位： Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, France.

作者： Fabienne,Marcellin ^[1] ; Abbas,Mourad ^[1] ; Maud,Lemoine ^[2] ; Charles,Kouanfack ^[3] ; Moussa,Seydi ^[4] ; Patrizia,Carrieri ^[1] ; Alain,Attia ^[5] ; Camelia,Protopopescu ^[1] ; Karine,Lacombe ^[6] ; Sylvie,Boyer ^[1]

作者单位： Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, France. ^[1] Department of Metabolism, Digestion and Reproduction, Division of Digestive Diseases, Section of Hepatology and Gastroenterology, St Mary's Hospital, Imperial College, London, UK. ^[2] Hôpital de Jour, Hôpital Central de Yaoundé, Cameroon.;Faculté de Médecine et des Sciences Pharmaceutiques, Université de Dschang, Dschang, Cameroon. ^[3] Service des Maladies Infectieuses et Tropicales, CHU Fann, Dakar, Senegal. ^[4] Service d'hépatologie, CHU Yopougon, Abidjan, Cote d'Ivoire. ^[5] Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France.;APHP, Hôpital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris, France. ^[6]

关键词 DAA, direct-acting antiviral EOT, end-of-treatment HRQL, health-related quality of life LMICs, low-to-middle income countries MCS, mental component summary MOS SF-12, Medical Outcomes Study 12-item short-form general health survey MOS, Medical Outcomes Study PCS, physical component summary PROs, patient-reported outcomes SOF/LDV, sofosbuvir plus ledipasvir SOF/RBV, sofosbuvir plus ribavirin SVR, sustained virological response W, week WHO, World Health Organization West Africa direct-acting antivirals health-related quality of life hepatitis C symptoms

DOI 10.1016/j.jhepr.2022.100665

PMID 36686592

发布时间 2023-02-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

JHEP reports

2023年5卷3期

100665页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览1

点击下载本期目录封面

JHEP reports

2023年5卷3期

100665页

检索历史清除

Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial).

JHEP reports

相似文献

同项目论文

JHEP reports

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial).

JHEP reports

相似文献

同项目论文

JHEP reports

相关期刊

检索历史清除